PerkinElmer Establishes Wholly Owned Subsidiary in India

Thane, Maharashtra, India

-- Customers to Benefit from Increased Investment in Direct Operations and Support

-- New Headquarters and Technical Support/Applications Center Underway

-- Jai Shankar is Appointed as President, PerkinElmer India

PerkinElmer, Inc., a global technology leader in Health Sciences and Photonics, has announced that it has acquired the remaining minority interest in PerkinElmer India Pvt. Ltd. from Labindia Instruments Pvt. Ltd. The transaction establishes PerkinElmer India Ltd. as a wholly owned subsidiary of PerkinElmer and underscores the company's commitment to supporting customers in India's thriving life science and analytical instrumentation markets.

"India represents a key growth market for PerkinElmer and we are committed to supporting the changing needs of the country's rapidly expanding health sciences market," said Gregory L. Summe, chairman and chief executive officer, PerkinElmer, Inc. "The establishment of a 100% direct operation in India will allow our customers to maintain their strong relationships with in-country sales and service experts, while providing them an increased level of applications and technical support, as well as direct access to a wider range of PerkinElmer products."

To further support its growth in the region, PerkinElmer plans to open a new India headquarters in Mumbai, as well as open a technical support and applications center in the second half of 2007. PerkinElmer India currently employs approximately 170 people in Bangalore, Baroda, Chennai, Hyderabad, Kolkatta, Mumbai, New Delhi, Pune and Thane.

PerkinElmer also announced the appointment of Jai Shankar as president, PerkinElmer India. Jai will be responsible for setting the strategic direction of PerkinElmer's business development activities across India, and overseeing the marketing, selling and support of PerkinElmer's full product and services portfolio to the country's growing community of scientists and researchers.

Jai brings to his new role extensive experience in sales and marketing, operations, new business development, strategic planning and P&L management. He joins PerkinElmer from Novartis Healthcare Pvt. Ltd., where he led its Global Services organization. Prior to this, Jai was with Glaxo SmithKline (GSK) and Unilever. While at GSK, he was responsible for its supply chain function and later managed the growth of a US$150-million business unit.

"We are pleased to have a leader of Jai's caliber and experience driving the growth of the new India organization," said Lapo Paladini, president of PerkinElmer Asia. "We also thank Labindia for our successful 25-year partnership, which has enabled us to move into this next phase of our growth."

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Source: Business Wire (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.